<DOC>
	<DOCNO>NCT00916149</DOCNO>
	<brief_summary>The purpose study determine levetiracetam ( patient focal seizure ) lamotrigine ( patient generalize seizure ) reduces occurrence interictal discharge . The study investigate possible correlation reduction interictal discharge improve cognitive performance .</brief_summary>
	<brief_title>Cognitive Effects Treatment Interictal Discharges</brief_title>
	<detailed_description>Subjects seizures study electroencephalography ( EEG ) offer medication prevention recurrent seizure . Those focal seizure treat levetiracetam , generalize seizure treat lamotrigine . Subjects undergo repeat EEG concurrent cognitive test initiation treatment . The propose study test 3 hypothesis : 1. treatment levetiracetam reduce focal interictal epileptiform activity , 2. treatment lamotrigine reduce generalize interictal epileptiform activity , 3. extent interictal epileptiform activity inversely associate performance neuropsychological battery computerize cognitive testing . Repeated cognitive/neuropsychological testing obtain steady state study drug approximately 2 month final dosage serve evaluate timecourse potential cognitive benefit .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Lamotrigine</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Inclusion Criteria 1865 year age Normal IQ ( â‰¥ 80 ) estimate Wechsler Test Adult Reading ( WTAR ) Able give consent The subject 's treating physician planning prescribe levetiracetam focal lamotrigine generalize seizure prevention Either symptomatic idiopathic seizure . Nonnative English speaking and/or multilingual Frequent seizure , since seizure impair cognitive function present confound variable . Subjects may one seizure one cluster seizure per month , cluster seizure include one seizure , patient return baseline . The cluster may occur two consecutive day one month . Seizure ( ) must occur within 3 day enrollment test . Those focal seizure evidence renal disease ( creatinine clearance le 80 ) exclude participation , levetiracetam clear kidney . Those focal seizure neutrophil count &lt; 1000/uL excluded participation , levetiracetam may lower white blood cell count . Those focal seizure irritability mood swing eligible participation , levetiracetam may exacerbate symptom . This determined selfreport , information obtain refer physician medical record . Those generalized seizure moderate severe liver dysfunction ( ChildPugh Grades B C ) exclude participation , lamotrigine clear liver propose dosing may tolerable population . This determined selfreport , information obtain refer physician , comprehensive metabolic panel ( routinely obtain newonset seizure ) medical record . Subjects pregnant eligible take part study , levetiracetam lamotrigine classify Pregnancy Category C drug may pose risk fetus . Women childbearing potential urine pregnancy test prior participation study . The urine pregnancy test repeat final study visit . Subjects epilepsy childbearing potential must use acceptable method birth control study , continue one month discontinuation study drug . If subject become pregnant time period , must notify investigator . Women breastfeed may participate study . Levetiracetam lamotrigine may pass breastmilk nursing mother , pose risk baby . Hypersensitivity lamotrigine , levetiracetam component product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Cognition</keyword>
	<keyword>Lamictal</keyword>
	<keyword>Lamotrigine</keyword>
	<keyword>Keppra</keyword>
	<keyword>Levetiracetam</keyword>
</DOC>